Thursday, Hollis-Eden Pharmaceuticals, Inc. (HEPH), at the World Congress on Insulin Resistance Syndrome, said, based on the early stage clinical trial, its investigational oral drug candidate, Triolex, appears to decrease the inflammatory markers and improved insulin sensitivity in obese insulin resistant subjects.
The additional data supported that the investigational drug is safe and well tolerated and significantly could improve insulin sensitivity, lower fasting blood glucose and insulin levels in obese insulin resistant subjects, when treated orally with 5 or 10 milligrams, twice daily for 28 days, as compared to placebo-treated subjects.
The company said that, Triolex, if developed successfully, could regulate both glucose homeostasis and inflammation, and thereby be a safer and better insulin sensitizer, which could be also beneficial in mitigating serious consequences associated with uncontrolled inflammation in cardiovascular disease.
The company said that if successfully developed, Triolex had the potential to be an anti-inflammatory drug for type 2 diabetes, without side effects of weight gain, edema and increased cardiovascular events, associated with the current Glitazone class of insulin sensitizing agents.
The stock closed Wednesday at $1.27 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.